Use of Prostacyclin and its Analogues in the Treatment of Cardiovascular Disease

Heart Disease

Volumn 1, Issue 1, 1999, Pages 29-40

  Fink, Andrew N ^a   Frishman, William H ^b,c   Azizad, Masoud ^b   Agarwal, Yogesh ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; ILOPROST; PROSTACYCLIN;

CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; HUMAN; PULMONARY HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; EPOPROSTENOL; HEART FAILURE, CONGESTIVE; HUMAN; HYPERTENSION, PULMONARY; ILOPROST; PLATELET AGGREGATION INHIBITORS;

EID: 0033086377     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. von Euler US. Zur Kenntnis der pharmakologishen wirkungen von Nativsekreten und Extrakten mannlicher accessorisher Geschlectsdruussen. Arch Exp Pathol Pharmacol 1934;75:78-84.
2. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from the arteries transforms prostoglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-665.
3. Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR, Johnson RA, et al. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976; 12:915-928.
4. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913.
5. 2) by layers of the arterial wall: an explanation for the antithrombotic properties of vascular endothelium. Thromb Res 1977;11:323-344.
6. 2 by cultured human endothelial cells. Biol Chem 1978;253:7138-7141.
7. 2 (prostacyclin) by cultured human bovine endothelial cells. Proc Nat Acad Sci U S A 1977; 74:3922-3926.
8. MacIntyre DE, Pearson JD, Gordon JE. Localization and stimulation of prostacyclin production in vascular cells. Nature 1978;271:549-551.
9. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1979;30: 293-331.
10. Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 1994;90:1643-1647.
11. Tateson JE, Moncada S, Vane JR. Effects of proctacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977;13:389-397.
12. 2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins 1978;16:17-22.
13. 2 in aqueous solutions. Prostaglandins 1978;15:943-954.
14. Wong PY, Sun FF, McGiff JC. Metabolism of prostacyclin in blood vessels. J Biol Chem 1978;253:5555-5557.
15. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apoprotein A-I (Apo-I): a novel function of Apo A-I. J Clin Invest 1988;82:803-807.
16. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-491.
17. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415.
18. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New Engl Med 1996;334:296-301.
19. Hinderliter AL, Park WW, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-1486.
20. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. New Engl J Med 1998;338:273-277.
21. Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:366-370.
22. Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995;75:34A-43A.
23. Cremona G, Higenbottam T. Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;75:67A-71A.
24. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995;75:51A-54A.
25. Rubin LJ, Barst RJ, Kaiser LR, Koener SK, Loyd JE, McGoon MD, et al. Primary pulmonary hypertension: ACCP Consensus Statement. Chest 1993; 104:236-250.
26. Pietra GG, Edwards WD, Kay JM, Rich S. Histopathology of primary pulmonary hypertension: a qualitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung and Blood Institute primary pulmonary hypertension registry. Circulation 1989;80:1198-1206.
27. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. New Engl J Med 1992;327:70-75.
28. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib A, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 1993;328:173-178.
29. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 1991;114:467-469.
30. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:236-250.
31. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349.
32. Rubin LJ. Calcium channel blockers in primary pulmonary hypertension. Chest 1985;88:257S-260S.
33. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-587.
34. Rubin LJ. Primary pulmonary hypertension: practical therapeutic recommendations. Drugs 1992;43:37-43.
35. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol 1995;75:63A-66A.
36. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B, Panayiotou H, et al. Acute and long-term effects of nifedipine on pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue diseases. Am J Cardiol 1991;68:1687-1691.
37. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Over PE, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. New Engl J Med 1982;306:557-564.
38. Pasque MK, Trulock EP, Kaiser LD, Cooper JD. Single lung transplantation for pulmonary hypertension: three months hemodynamic follow-up. Circulation 1991;84:2275-2279.
39. Doud JR, McCabe MM, Montoya A, Garrity ER. The Loyola University lung transplant experience. Arch Intern Med 1993;153:2769-2773.
40. Galie N, Ussi G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;75:55A-62A.
41. Marshall RJ, Helmholz HF, Shepherd JT. Effect of acetylcholine on pulmonary vascular resistance in a patient with idiopathic pulmonary hypertension. Circulation 1959;20:391-395.
42. Morgan MJ, McCormack DG, Griffiths MJD, Morgan CJ, Barnes PJ, Evans TWl. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991;84:1145-1149.
43. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038-2047.
44. Rozkovec A, Stradling JR, Shepherd G, McDermot J, Oakley CM, Dollery CT. Prediction of favorable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine. Br Heart J 1988;59:696-705.
45. Palewsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholine at screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990;82:2018-2026.
46. Scrader BJ, Inbar S, Kaufman L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060-1064.
47. Inbar S, Schrader BJ, Kaufmann E, Vestal RE, Rich S. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol 1993;21:413-418.
48. Jolliet P, Bulpa P, Thorens JB, Ritz M, Chevrolet JC. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive abillity and consequences on haemodynamics and gas exchange. Thorax 1997;52:369-372.
49. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-389.
50. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann J, Georgiou D, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenolol infusion. J Am Coll Cardiol 1997;30: 343-349.
51. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with refractory congestive heart failure. Am J Cardiol 1982;50:320-324.
52. 2) increases left ventricular ejection fraction (LVEF). Prostaglandins Leukot Essent Fatty Acids 1989;36:149-154.
53. McKenna WJ, Swedberg K, Zannad F, Darius H, Soler-Soler J, Handberg E, et al. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: results of FIRST (abstract). Eur Heart J 1994;15:36A.
54. Montalescot G, Drobinski G, Meurin P, Maclouf J, Sotirov I, Philippe F, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998;82:749-755.
55. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Tollemeto D, Mari L, et al. Myocardial ischemia induced by prostacyclin and iloprost. Clin Pharmacol Ther 1985;38:101-108.
56. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Tollemeto D, Macri N, et al. Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures. Am Heart J 1987;113:234-240.
57. Gershlick AH, Spriggins D, Davies SW, Syndercombe Court YD, Timmins J, Timmis AD, et al. Failure of epoprostenol to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomized placebo controlled trial. Br Heart J 1994;71:7-15.
58. Jugdutt BJ, Hutchins GM, Bulkley BH, Becker LC. Dissimilar effect of prostacyclin, prostaglandin E1 and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 1981;49:685-700.
59. Ogletree MI, Lefer AM, Smith JB, Nicolaou KC. Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 1979;56: 95-103.
60. Ribeiro L, Brandon T, Hopkins D, Reduto LA, Taylor AA, Miller RR. Prostacyclin in experimental myocardial ischemia: effect on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 1981; 47:835-840.
61. Starnes VA, Primm RK, Woosley RL, Oates JA, Hammon JW. Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. J Cardiovasc Pharmacol 1982;4:765-769.
62. Kiernan FJ, Kluger J, Regnier J, Rutkowiski M, Fieldman A. Epoprostena sodium (prostacyclin) infusion in acute myocardial infarction. Br Heart J 1986; 56:428-432.
63. Henriksson P, Edhag O, Wennmalm A. Prostacyclin offers protection against early extension of acute myocardial infarction. Adv Prostagl Thromb Leukotr Res 1987;17:435-436.
64. Armstrong PW, Langevin LM, Watts DG. Randomized trial of prostacyclin infusion in acute myocardial infarction. Am J Cardiol 1988;61:455-457.
65. Blasko G, Berentey E, Harsanyi A, Sas G. Intracoronarily administered protacyclin and streptokinase for treatment of myocardial infarction. Adv Prostat Thromb Leukotr Res 1983;11:385-390.
66. Uchida Y, Hanai T, Hasegawa K, Kawamura K, Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Adv Prostagl Thromb Leukotr Res 1983;11:377-383.
67. Hackett D, Davies G, Attilio M. Effect of prostacyclin on coronary occlusion in acute myocardial infarction. Int J Cardiol 1990;26:53-58.
68. 2) in peripheral arterial disease. Thromb Res 1981;22:481-490.
69. Pardy BJ, Lewis JD, Eastcott HHG. Preliminary experience with prostaglandin E1 and E2 in peripheral vascular disease. Surgery 1981;88:826-832.
70. Vermylen J, Chamore DAF, Machin SJ, Defreyn CR, Verstraete M. Prostacyclin in unperable ischemic rest pain. Acta Ther 1980;6:33.
71. Belch JJF, McArdle B, Pollock JG, Forbes CD, McKay A, Leiberman P, et al. Epoprostenol (prostacyclin) and severe arterial disease: a double-blind trial. Lancet 1983;1:315-317.
72. Belch JJF, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome a double-blind control trial. Lancet 1983;1:313-315.
73. 2). Br J Dermatol 1982;106:81-89.
74. Kingma K, Wollersheim H, Thein T. Double-blind, placebo-controlled study on hemodynamics in severe Raynaud s phenomenon: the acute vasodilatory effect is not sustained. J Cardiovasc Pharmacol 1995;26:388-393.
75. Moodley J, Gouws E. A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. Br J Gynecol 1992;99:727-730.
76. Caruana RJ, Smith MC, Clyne D, Crow JW, Zinn JM, Diehl JH. Controlled study of heparin verses epoprostenol sodiun (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purification 1991;9:296-304.
77. Dibble JB, Kalra PA, Orchard MA, Turney JH, Davies JA. Prostacyclin and iloprost do not effect action of standard dose heparin on hemostatic function during hemodialysis. Thromb Res 1988;49:385-392.
78. Aren C, Feddersen K, Radegran K. Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg 1983;36:49-54.
79. DiSesa VJ, Huval W, Lelcuk S, Jonas R, Maddi R, Lee-Son S, et al. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. Ann Thorac Surg 1984; 38:514-519.
80. Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function. J Lab Clin Med 1987;109:184-190.
81. Saniabadt AR, Belch JJF, Lowe GDO, Barbenel JC, Forbes CD. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregations of human platelet in whole blood. Hemostasis 1987;17:147-153.
82. 2 in vitro. Naunyn Schmiedebergs Arch Pharmacol 1981;316:252-255.
83. Lye RH, Parsons AA, Whalley ET. Effect of iloprost (ZK 36374) and prostacyclin on in vitro human cerebral arteries (abstract). Br J Pharmacol 1986;9: 691P.
84. Schroder G, Beckman R, Schillinger E. Studies on vasorelaxant effects and mechanisms of iloprost in isolated preparations. In, Gryglewski RJ, Stock G (eds.): Prostacyclin and Its Stable Analogue Iloprost. Berlin: Springer Verlag, 1987;119-137.
85. Bergman G, Kiff PS, Atkinson L, Kerkez S, Jewitt DE. Dissociation of platelet aggregation and vasodilation with iloprost: a stable orally active, prostacyclin derivative (abstract). Circulation 1983;68(suppl III):398.
86. Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H. Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther 1984;36:464-469.
87. Krause W, Humpel M, Hoyer GA. Biotransformation of the stable prostacyclin analogue, iloprost, in the rat. Drug Metab 1984;12:645-651.
88. Hildebrand M, Krause W, Fabian H, Koziol T, Neumayer HH. Pharmacokinetics of iloprost in patients with chronic renal failure and maintenance hemodialysis. Int J Clin Pharmacol Res 1990;10:285-292.
89. Hildebrand M, Krause W, Angeli P, Koziol T, Gatta A, Merkel C, et al. Pharmacokinetics of iloprost in patients with hepatic dysfunction. Int J Clin Pharmacol Ther Toxicol 1990;28:430-434.
90. Scott JP, Higenbottam T, Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract 1990;44:231-234.
91. De La Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994;37:1528-1533.
92. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Acrosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-824.
93. Mikhail G, Gibbs J, Richardson M, Wright G, Khaghani A, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997;18:1499-1504.
94. Dormandy J. Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischemia. Therapie 1991;46:319-322.
95. United Kingdom Severe Limb Ischemia Study Group. Treatment of limb threatening ischemia with intravenous iloprost: a ramdomized double-blind placebo controlled study. Eur J Vasc Surg 1991;5:511-516.
96. Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischemia of thromboangiitis obliterans. Lancet 1990;335:555-557.
97. Watson HR, Belcher G. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 1991;50:359-361.
98. Darton K, Tanner SB, Watson HR, Csuka MH, Black CM. Long term follow-up of iloprost infusion in patients with connective tissue disease using infrared thermography (abstract). Br J Rheum 1991;30(suppl 2):76.
99. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. Br Med J 1989;298:561-564.
100. Belch JJF, Capell HA, Cooke ED, Kirby JDT, Lau CS, Madhok R, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicenter placebo controlled study. Ann Rheum Dis 1995;54:197-200.
101. De Caterina R, Pelosi G, Carpeggiani C, Bernini W, Giannessi D, Lazzerini G, et al. Iloprost in Prinzmetal's angina. Am J Cardiol 1986;58:553-554.
102. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Mari L, Puddo P, et al. Effects of iloprost, a stable prostacydin analog, on exercise capacity and platelet aggregation in stable angina pectoris. Am J Cardiol 1986;58:453-459.
103. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, et al. Combined tissue-type plasminogen activator and prostacydin therapy for acute myocardial infarction. J Am Coll Cardiol 1989;14:877-884.
104. Martin W, Spyt T, Thomas I, Davidson JF, Wheatley DJ. Quantification of extra-corporeal platelet deposition in cardiopulmonary bypass: effects of ZK 36374, a prostacydin analogue. Eur J Nucl Med 1989;15:128-132.
105. Massonnet-Castel S, Farge D, Tournay D, Dubois D, Fabiani JN. Utilisation d'une prostacydin de synthese en circulation extracorporelle. Presse Med 1992; 25:113-118.
106. Popat KD, Pitt B. Hemodynamic effects of prostaglandin E1 infusion in patients with acute myocardial infarction and left ventricular failure. Am Heart J 1982;103:485-489.
107. Sharma B, Wyeth RP, Gimenez, HJ, Franciosa JA. Intercoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. Am J Cardiol 1986;58: 1161-1166.
108. Awan NA, Evenson MK, Needham KE, Beattie JM, Amsterdam EA, Mason DT. Cardiocirculation and myocardial energetic effects of prostaglandin E1 in severe left ventricular failure due to chronic coronary heart disease. Am Heart J 1981;102:703-709.
109. Clifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980;281:1031-1034.
110. Lucas GS, Simms MH, Caldwell NM, Alexander SJ, Stuart J. Hemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome. J Clin Pathol 1984;37:870-873.
111. Pardy BJ, Lewis JD, Eastcott HH. Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease. Surgery 1980;88:826-832.
112. Rubis LJ, Stephenson LW, Johnston MR, Nagaraj S, Edmund LH Jr. Comparison of effects of prosraglandin E1 and nitroprusside on pulmonary vascular resistance in children after open-heart surgery. Ann Thorac Surg 1981;32: 563-570.
113. Flohe L, Bohlke H, Frankus E, Kim SM, Lintz W, Loschen G, et al. Designing prostacydin analogues. Arzneimittelforschung 1983;33:1240-1248.
114. 2 analogue (abstract). In, Proceedings of the Sixth International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 1986;443.
115. Barth H, Lintz W, Michel G, Osterloh G, Seipp U, Flohë L. Inhibition of platelet aggregation by intravenous administration of the biochemically stable prostacyclin analogue CG 4203 in man (abstract). Naunyn Schmiedebergs Arch Pharmacol 1983;324(Suppl):R60.
116. Darius H, Kopp H, Mulfinger A, Spielberger M, Todt M, Schuster CJ, et al. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease. Prog Clin Biol Res 1989;301:417-421.
117. Virgolini I, Fitscha P, O'Grady J, Barth H, Sinzinger H. Effects of taprostene, a chemically stable prostacydin analogue, in patients with ischemic peripheral vascular disease: a placebo controlled double-blind trial. Prostaglandins Leukot Essent Fatty Acids 1989;38:31-35.
118. Hopf R, Schofl E, Frings M, Sohngen W. Einfluss des prostacyclin analogons taprostene auf die ischamische ST-streckensenkung im belastungs-EKG koronarkranker. Z Kardiol 1994;83:258-263.
119. Bar FW, Meyer J, Michels R, Uebis R, Lange S, Barth H, et al. The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Eur Heart J 1993;14:1118-1126.
120. Linet OI, Luderer JR, Froeschke M, Welch S, Metzler CM, Eckert SM. Ciprostene in patients with peripheral vascular disease: an open-labeled, tolerance trial. Prostaglandins Leukot Essent Fatty Acids 1988;34:9-14.
121. The Ciprostene Study Group. The effect of ciprostene in patients with peripheral vascular disease (PAD) characterized by ischemic ulcers. J Clin Pharmacol 1991;31:81-87.
122. Darius H, Nixdorff U, Zander J, Rupprecht HJ, Erbel R, Meyer J. Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty. Agents Actions Suppl 1992;37:305-311.
123. Patterson JH, Adams KF, Gheorghiade M, Bourge RC, Sueta CA, Clark SW, et al. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. Am J Cardiol 1995;75:26A-33A.
124. Hildebrand M, Staks T, Nieuweboer B. Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms. Eur J Clin Pharmacol 1990;39:149-153.
125. Lau CS, McLaren M, Saniabadi A, Scott N, Belch JJ. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis: a preliminary study. Clin Exp Rheumatol 1991;9:271-273.
126. Lau CS, Belch JJ, Madhok R, Cappell H, Herrick A, Jayson M, et al. A randomized, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 1993;11:35-40.
127. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996;27:788-793.
128. Ichida F, Uese K, Tsubata S, Hashimoto I, Hamamichi Y, Fukahara K, et al. Additive effect of beroprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997;80:662-664.
129. Okano Y, Hoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension (letter). Lancet 1997; 349:1365.